

Aberystwyth University

Functional Expression of Parasite Drug Targets and Their Human Orthologs in Yeast

Bilsland, Elizabeth; Pir, Pinar; Gutteridge, Alex; Johns, Alexander; King, Ross D.; Oliver, Stephen G.; Geary, Timothy G.

Published in:

PLoS Neglected Tropical Diseases

DOI:

[10.1371/journal.pntd.0001320](https://doi.org/10.1371/journal.pntd.0001320)

Publication date:

2011

Citation for published version (APA):

Bilsland, E., Pir, P., Gutteridge, A., Johns, A., King, R. D., Oliver, S. G., & Geary, T. G. (Ed.) (2011). Functional Expression of Parasite Drug Targets and Their Human Orthologs in Yeast. *PLoS Neglected Tropical Diseases*, 5(10), [e1320]. <https://doi.org/10.1371/journal.pntd.0001320>

General rights

Copyright and moral rights for the publications made accessible in the Aberystwyth Research Portal (the Institutional Repository) are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Aberystwyth Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Aberystwyth Research Portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

tel: +44 1970 62 2400

email: is@aber.ac.uk

Functional Expression of Parasite Drug Targets and Their Human Orthologs in Yeast

Elizabeth Bilsland¹, Pinar Pir¹, Alex Gutteridge¹, Alexander Johns¹, Ross D. King², Stephen G. Oliver^{1*}

¹ Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, Cambridge, United Kingdom, ² Department of Computer Science, Aberystwyth University, Aberystwyth, Ceredigion, United Kingdom

Abstract

Background: The exacting nutritional requirements and complicated life cycles of parasites mean that they are not always amenable to high-throughput drug screening using automated procedures. Therefore, we have engineered the yeast *Saccharomyces cerevisiae* to act as a surrogate for expressing anti-parasitic targets from a range of biomedically important pathogens, to facilitate the rapid identification of new therapeutic agents.

Methodology/Principal Findings: Using pyrimethamine/dihydrofolate reductase (DHFR) as a model parasite drug/drug target system, we explore the potential of engineered yeast strains (expressing DHFR enzymes from *Plasmodium falciparum*, *P. vivax*, *Homo sapiens*, *Schistosoma mansoni*, *Leishmania major*, *Trypanosoma brucei* and *T. cruzi*) to exhibit appropriate differential sensitivity to pyrimethamine. Here, we demonstrate that yeast strains (lacking the major drug efflux pump, Pdr5p) expressing yeast (^{Sc}DHFR1), human (^{Hs}DHFR), *Schistosoma* (SmDHFR), and *Trypanosoma* (^{Tb}DHFR and ^{Tc}DHFR) DHFRs are insensitive to pyrimethamine treatment, whereas yeast strains producing *Plasmodium* (^{Pf}DHFR and ^{Pv}DHFR) DHFRs are hypersensitive. Reassuringly, yeast strains expressing field-verified, drug-resistant mutants of *P. falciparum* DHFR (^{Pf}dhfr^{511,59R,108N}) are completely insensitive to pyrimethamine, further validating our approach to drug screening. We further show the versatility of the approach by replacing yeast essential genes with other potential drug targets, namely phosphoglycerate kinases (PGKs) and N-myristoyl transferases (NMTs).

Conclusions/Significance: We have generated a number of yeast strains that can be successfully harnessed for the rapid and selective identification of urgently needed anti-parasitic agents.

Citation: Bilsland E, Pir P, Gutteridge A, Johns A, King RD, et al. (2011) Functional Expression of Parasite Drug Targets and Their Human Orthologs in Yeast. PLoS Negl Trop Dis 5(10): e1320. doi:10.1371/journal.pntd.0001320

Editor: Timothy G. Geary, McGill University, Canada

Received: May 29, 2011; **Accepted:** July 28, 2011; **Published:** October 4, 2011

Copyright: © 2011 Bilsland et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by grant BB/F008228/1 from the UK Biotechnology and Biological Sciences Research Council to SGO and RDK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: sgo24@cam.ac.uk

Introduction

Parasitic diseases such as malaria, schistosomiasis, leishmaniasis, sleeping sickness, and Chagas disease affect millions of people every year, leading to severe morbidity and death. For example malaria, caused by parasites of the genus *Plasmodium*, kills 1–3 million people every year (<http://www.who.int/mediacentre/factsheets/fs094/en/index.html>). The disease is primarily treated by chloroquine, artemisinin, and antifolates (e.g. pyrimethamine). However, *Plasmodium* spp. have become resistant to all of these drugs [1]. Schistosomiasis, caused by the blood fluke *Schistosoma*, is the second most important parasitic disease worldwide, affecting ca. 207 million people (<http://www.who.int/mediacentre/factsheets/fs115/en/index.html>) [2], and causing the death of greater than 300,000 individuals per annum [3]. Schistosomiasis is commonly treated through administration of praziquantel, but the sole use of this drug against all human infective schistosome species raises the concern that drug-resistant parasites may develop [4]. Sleeping sickness (or African trypanosomiasis), caused by *Trypanosoma brucei*, infects about 300,000 people each year leading to about 40,000 deaths [5,6]. Chagas disease, caused by *T. cruzi*, is endemic to Latin America, where ca. 17 million people are infected,

leading to about 21,000 deaths reported each year [7]. Very few drugs are available for the treatment of patients infected with *Trypanosoma* spp. and none is satisfactory due to low efficacy, high cost, or unacceptable side effects [8,9,10]. Leishmaniasis, caused by *Leishmania* spp. is endemic in 88 countries affecting 12 million people (<http://www.who.int/leishmaniasis/en/>). It is traditionally treated with antimony compounds, but resistance to this class of drugs is increasing and very few novel drugs are under development. All of this demonstrates that the design or discovery of novel antiparasitic drugs is a global imperative.

For the past 30 years, the yeast *Saccharomyces cerevisiae* has been used successfully as a vehicle for the expression of heterologous proteins with the aim of understanding their function, producing high levels of recombinant protein, or studying the effect of drugs on defined targets (for review see [11]). By performing genome-wide drug sensitivity screens (chemogenomic profiling) [12,13,14,15,16,17] of yeast mutants with the antimalarials quinine [18], St. John's Wort [19] and artemisinin [20], researchers were able to identify their primary targets as well as identify potential side effects. Furthermore, several groups have been able to complement yeast loss-of function mutations by expressing coding sequences from parasites such as *Plasmodium*

Author Summary

Parasites kill millions of people every year and leave countless others with chronic debilitating disease. These diseases, which include malaria and sleeping sickness, mainly affect people in developing countries. For this reason, few drugs have been developed to treat them. To make matters worse, many parasites are developing resistance to the drugs that are available. Thus, there is an urgent need to develop new drugs, but this is hampered by the fact that most parasites are difficult or impossible to grow in the laboratory. To address this, we have engineered baker's yeast to be dependent on the function of enzymes from either parasites or humans. In all, our engineered yeast constructs encompass six parasites (causing malaria, schistosomiasis, leishmaniasis, sleeping sickness, and Chagas disease) and three different enzymes that are known or potential drug targets. Further, we have increased yeast's sensitivity to drugs by deleting the gene for its major drug efflux pump. Because yeast is robust and easy to grow in the laboratory, we can use a robot to screen for drugs that will kill yeast dependent on a parasite enzyme, but not touch yeast dependent on the equivalent human enzyme.

[21,22], *Schistosoma* [23,24,25], *Leishmania* [26] or *Trypanosoma* [6,27,28,29,30,31].

Yeast cells expressing parasite proteins potentially provide a well-characterised platform for functional studies of heterologous proteins as well as for screens attempting to identify novel drugs including antiparasitics [32,33,34,35]. For instance, Geary and co-workers expressed potential drug targets for *Haemonchus contortus* (wireworm, an important parasite of ruminants) in *Escherichia coli* [36,37] and later in *Saccharomyces cerevisiae* [38], and pioneered the development of high-throughput drug screens for antiparasitics in yeast [38].

A well-characterised anti-parasitic drug target is dihydrofolate reductase (DHFR). DHFR is the enzyme responsible for converting dihydrofolate into tetrahydrofolate, an intermediate in the synthesis of purines, thymidylc acid, and certain amino acids (e.g. methionine). DHFR is present in organisms ranging from bacteria to humans and is the target of pyrimethamine treatment of malaria and human tumours, since rapidly growing cells require folate to produce thymine [39]. Sibley and co-workers [22,40,41] have done extensive work on the complementation of yeast *dhfr1* mutations by overexpression of human and *Plasmodium* DHFRs and demonstrated the suitability of the strains for drug screens in plate assays.

Phosphoglycerate kinase (PGK) is a central enzyme in glycolysis and gluconeogenesis; it catalyzes the transfer of high-energy phosphoryl groups from the acyl phosphate of 1,3-bisphosphoglycerate to ADP to produce ATP. PGKs are essential for the blood stages of parasites but the human enzyme is not expressed in erythrocytes; therefore, the enzyme has been proposed as a drug target [42,43].

N-myristoyltransferase (NMT) is an enzyme responsible for the co- and post-translational modification of proteins by transferring myristate groups to N-terminal glycine residues, allowing their targeting to various membranes [5,44]. NMTs are essential enzymes conserved from kinetoplastid parasites to humans and have been successfully demonstrated as drug targets [5].

In spite of the pressing need for new treatments targeting neglected diseases, pharmaceutical companies have had little interest in the research and development of new medicines

towards diseases affecting overwhelmingly or exclusively developing countries [45,46]. Thankfully, with the investment of funds from organizations such as the Bill and Melinda Gates Foundation, Medicines for Malaria Venture (MMV), the Drugs for Neglected Diseases initiative (DNDi), and the Institute for One World Health (IOWH) this scenario is changing [47,48]. Now, pharmaceutical giants such as Novartis [49], GSK [50], Pfizer (just to name a few) investing great efforts in the development of novel antimalarials (www.mmv.org/research-development/science-portfolio). However, due to the diversity of parasite species and their complex life cycles, the development of inexpensive and rapid drug screening methods is a constant challenge. Various groups have developed efficient high-throughput drug screening methods based on intact parasites [51,52,53,54]. However, these are specific to one or a few parasite species and do not always provide information concerning the target of the hit compound. Conversely, the standard alternative of using pure proteins as targets can be unsatisfactory because the assay neglects all other biological interactions of the candidate compounds [35]. To meet this challenge, we have developed a series of yeast strains that can be used to screen for drugs against multiple drug targets from multiple parasites with a single experimental set-up.

Methods

Construction of plasmid maps and phylogenetic trees

We constructed plasmid maps and Genbank files of the constructs expressing heterologous protein using the program CLC Genomics Workbench. We translated the coding regions of each of the proteins and performed protein alignments of them against *Saccharomyces cerevisiae* Dfr1p, Nmt1p and Pkg1p. We constructed the similarity tree using the standard settings from CLC Genomics Workbench (neighbor-joining, bootstrap analysis, 100 replicates).

Strain and plasmid constructs

The DHFR/PGK/NMT-coding regions of *Schistosoma mansoni* (*Sm*), *Saccharomyces cerevisiae* (*Sc*), *Leishmania major* (*Lm*), *Trypanosoma cruzi* (*Tc*) and *T. brucei* (*Tb*) were PCR amplified from genomic DNA templates and cloned into pCM188 [55]. The following plasmids were constructed: pCMSmDHFR (pCM188 with the complete open reading frame of *Schistosoma mansoni* DHFR under the control of the tetracycline regulatable promoter TetO2), pCM^{Sc}DHFR, pCM^{Lm}DHFR, pCM^{Tc}DHFR, pCM^{Tb}DHFR, pCMSmPGK, pCM^{Lm}PGK, pCM^{Tc}PGK, pCM^{Tb}PGK, pCMSmNMT, pCM^{Lm}NMT, pCM^{Tc}NMT, pCM^{Tb}NMT (Table S1).

Human (*Hs*) PGK and NMT2 were PCR amplified from a human cerebellum cDNA library and cloned into pCM188 to produce pCM^{Hs}PGK and pCM^{Hs}NMT2 (Table S1).

The DHFR coding sequences from human, *Plasmodium falciparum* (*Pf*), and *P. vivax* (*Pv*), as well as PGK and NMT from *P. vivax*, were synthesised by GENEART with a codon usage suitable for expression in yeast. These synthetic constructs were sub-cloned into pCM188 to generate pCM^{Hs}DHFR, pCM^{Pf}DHFR, pCM^{Pv}DHFR, pCM^{Pv}PGK and pCM^{Pv}NMT (Table S1).

The DHFR mutations N51I, C59R and S108N confer resistance to antifolates in wild *Plasmodium falciparum* populations; we designate such resistant alleles by the preceding superscript *Pfr* and give the amino-acid changes in parentheses in a succeeding superscript. Two rounds of site-directed mutagenesis were performed to introduce these mutations into pCM^{Pf}DHFR to generate pCM^{Pfr}*dhfr*^(51I,59R,108N) (Table S1). All constructs were verified by sequencing (Figures S1, S2, S3, S4, S5, S6, S7, S8 and

Text S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, S13, S14, S15, S16, S17, S18, S19, S20, S21).

Deletions of the yeast *PDR5* coding sequence (specifying the major drug efflux pump) from *dfi1*, *pgk1* and *nmt1* heterozygous mutant strains were performed as previously described [56]. pCM-*DHFR* constructs were transformed into *dfi1Δ::KanMX/DFR1 pdr5Δ::HisMX/PDR5* strains (BY4743 background [57]). pCM-*PGK* constructs were transformed into *pgk1Δ::KanMX/PGK1 pdr5Δ::HisMX/PDR5* strains (BY4743 background). pCM-*NMT* constructs were transformed into *nmt1Δ::KanMX/NMT1 pdr5Δ::HisMX/PDR5* strains (BY4743 background). Heterozygous diploid strains were then sporulated and dissected using a micromanipulator (Singer MSM). Derived haploids with the genotype *dfi1Δ::KanMx MET15 lys2Δ0 MATα*, *pgk1Δ::KanMx MET15 lys2Δ0 MATα* or *nmt1Δ::KanMx met15 LYS2 MATα* were selected for drug screens (Table S2).

Growth conditions

Standard growth conditions and either YPD (2% peptone, 1% yeast extract, 2% glucose) or YNB-glucose (0.68% yeast nitrogen base, 2% ammonium sulphate, 2% glucose) with the relevant supplements were used for all assays.

Liquid growth assays and maximum growth rate calculations

Cultures of wild type (BY4741) and transformant yeast strains were inoculated into 200 μl of YPD in the wells of 96-well microtiter plates and grown for 40 hours at 30°C. Growth was monitored with the BMG Optima multiplate reader. Each sample was present in quadruplicates, distributed randomly throughout the plate and OD₅₉₅ measurements were made every 10 minutes. A 384-well plate (with 70 μl of YPD + doxycycline) was prepared in a similar manner.

The OD readings from the plate reader were log-transformed and 7 consecutive readings were used to calculate exponential growth rate of the culture in each well. These exponential growth rates were then normalized by dividing by the average exponential growth rate of the wild type culture grown on the same plate. Normalized growth rates were averaged across the 4 or 5 replicates and standard deviations calculated.

Plate assays for drug sensitivity

Serial dilutions (5x) of stationary phase cultures were prepared in 96-well plates and replicated onto agar plates manually or in quadruplicate onto agar plates using a robot (Singer RoToR). Cells were allowed to grow for 2 days at 30°C.

Quantification of growth on agar plates

Strains were spotted in four replicates (Figure S10). Each pair of rows on the image corresponds to a strain, spotted in increasing dilutions (1:1, 1:5, 1:25 ...) in blocks of four. The images of the plates were produced in Gel Doc 2000 (BioRad) and saved as .jpg files. Matlab was used to convert the images to three-dimensional matrices, the first and second dimensions were the vertical and horizontal dimensions of the image and third dimension was the colour channel in RGB 24-bit format. As the images were saved in grey scale, choice of channel did not make a major impact on quantification of colonies; third channel (Green) was used.

The average intensities of pixels on each column and row in the image were calculated, intersection points of rows and columns with highest average intensity among their neighbours (in a window of 5×5) were set as the spot or colony centres. Once the colony centres were set, a 16 pixels×16 pixels diamond shape

colony frame was set around each colony centre, and average intensity was calculated for each colony frame. Then the pixels with 50% larger intensity than the average of the colony frame were counted and recorded as the colony size.

Results

Defining the drug targets

We have defined our candidate drug targets based on the following criteria: (i) the target should be an enzyme that is essential in yeast (this permits verification of the functional expression of the target); (ii) the target should be essential, or predicted to be essential, in most parasites; (iii) it may be present in human (a 'humanized' yeast strain will be used as a control in the screens); (iv) there should be a low similarity between human and parasite proteins; (v) the target should be one suggested by the TDR targets database (<http://tdrtargets.org/>). Combining these criteria, we selected 4 drug targets for expression in yeast: dihydrofolate reductase (DHFR, EC:1.5.1.3), phosphoglycerate kinase (PGK, EC:2.7.2.3), N-myristoyl transferase (NMT, EC:2.3.1.97), and farnesyl pyrophosphate synthetase (FPS, EC:2.5.1.1, EC:2.5.1.10). As explained in the Introduction, all of these enzymes have previously been proposed as useful targets for antiparasitic drugs, and many have been used in drug screens [5,22,41,42,43,44,58].

Complementation

We have constructed a series of four plasmids containing the coding sequences (cds) for human DHFR, PGK, NMT, and FPS and transformed these into diploid yeast strains that are heterozygous deletion mutants for the gene encoding the corresponding essential enzyme, namely: *DFR1* (ScDHFR), *PGK1* (ScPGK), *NMT1* (ScNMT) or *ERG20* (ScFPS). The transformed diploids were then sporulated. Two of the four haploid spores in the tetrad will carry the deletion for the essential yeast gene and will only grow if that mutation is complemented by the orthologous human cds. We observed that the overexpression of the cds for human DHFR (a synthetic gene codon-optimised for expression in yeast was used), PGK or NMT2 could complement the essential function of the yeast deletions (Figure 1), whereas human FPS could not complement the deletion of the yeast FPS (data not shown). We then constructed plasmids expressing codon-optimized cds for *Plasmodium vivax* DHFR, NMT and PGK, *P. falciparum* DHFR and drug resistant *P. falciparum* dhfr, and verified that these heterologous sequences could also complement the yeast deletions. We constructed strains expressing cds for *Schistosoma mansoni*, *Leishmania major*, *Trypanosoma cruzi* and *T. brucei* DHFRs and NMTs, and found that each of them could complement yeast deletions, albeit with varying efficiencies (Figure 1). The same was true for each of the *Schistosoma mansoni*, *Trypanosoma cruzi*, and *T. brucei* PGKs tested. We tested whether cds for the different *Leishmania major* PGKs – the cytosolic PGKB, the glycosomal PGKC, and the putative PGK LmjF30.3380 – could complement a yeast *pgk1* deletion mutation. We found that only PGKB could complement the yeast deletion and resulted in a slow-growth phenotype (approximately 64% of the maximum growth rate of a wild-type strain) even with full expression of the heterologous protein (Figure 1).

Plasmid maps for all of these plasmids are shown in Figures S1, S2, S3, S4, S5, S6, S7, S8 and the full sequences of the plasmids can also be found in the Supplementary Material (Text S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, S13, S14, S15, S16, S17, S18, S19, S20, S21).




Figure 1. Complementations of yeast *dfr1*, *nmt1* and *pgk1* deletion mutants with human and parasite orthologs. A) Maximum growth rates of yeast strains expressing cds for heterologous dihydrofolate reductases (DHFRs), N-myristoyl transferases (NMTs) or phosphoglycerate kinases (PGKs) from human (Hs), *Leishmania major* (Lm), *Plasmodium falciparum* (Pf and PfR), *P. vivax* (Pv), *Schistosoma mansoni* (Sm), *Trypanosoma brucei* (Tb) or *T. cruzi* (Tc). B) Phylogenetic tree and maximum growth rate (% of wild-type growth) of the heterologous NMTs, DHFRs and PGKs. All strains are *pdr5Δ* mutants.
doi:10.1371/journal.pntd.0001320.g001

Modulated expression

We cloned cds for all of the heterologous proteins into pCM188 plasmids, under the control of a TetO2 promoter, to allow the modulated expression of each drug target in yeast. TetO2 is a powerful constitutive promoter but can be repressed by the addition of a tetracycline analogue (doxycycline) to the growth medium. Thus, normal growth conditions result in the full expression on the cloned cds; however, by adding doxycycline, we can reduce the expression of the parasite or human cds to levels that should be inversely proportional to the concentration of doxycycline added. We measured the growth rate of the parasite mimetic or human mimetic yeast strains in the presence of 2, 5, 10

or 20 mg/L doxycycline and found that the reduction in growth rate of yeast expressing human or parasite cds for either DHFR or NMT were relatively insensitive to the addition of doxycycline ($\leq 25\%$) growth-rate inhibition (Figure S9). In contrast, addition of doxycycline to strains express cds for PGK displayed up to 75% growth-rate upon doxycycline treatment (Figure S9). While these results indicate that only small amounts of the heterologous enzymes are often sufficient to achieve full complementation of the yeast deletion mutation, we demonstrate below that reduction in enzyme concentration achieved by inhibiting promoter activity with doxycycline is sufficient to enhance the sensitivity of yeast growth to the action of drugs that inhibit the activity of target enzymes to a useful extent.

Plate assays

PGKs and NMTs are fairly novel drug targets and therefore we had no access to specific inhibitors for the different species tested. However, *Plasmodium* DHFRs are classic drug targets, which can be specifically inhibited by the antimalarial drug pyrimethamine. Therefore, we performed drug sensitivity assays (on agar plates) of the different yeast transformants expressing parasite mimetic or human DHFRs in the presence of various concentrations of pyrimethamine. We found that yeast strains expressing *Plasmodium vivax* DHFR ($y^{Pv}DHFR$) showed sensitivity to concentrations of pyrimethamine ranging from 10 to 500 μ M (Figure 2, upper panels). Yeast strains expressing *Plasmodium falciparum* DHFR ($y^{Pf}DHFR$) showed sensitivity to concentrations of pyrimethamine ranging from 100 to 500 μ M (Figure 2, upper panels). No other strain showed sensitivity to the pyrimethamine concentrations tested. Importantly, by modulating the expression of the heterologous cds by adding 5 mg/L doxycycline to the growth media, it was possible to increase the sensitivity of the strains to pyrimethamine by approximately 50-fold (Figure 2, lower panels).

Effect of a *pdr5* deletion on pyrimethamine sensitivity

With the aim of further increasing the sensitivity of our assays, we deleted the *PDR5* gene, which encodes the major yeast multidrug export pump, from all of our strains and tested the effect of such a deletion on the pyrimethamine sensitivity of strains expressing heterologous DHFRs. We spotted (using a Singer RoTor robot) serial dilutions of *PDR5* and *pdr5Δ* strains onto rectangular agar plates containing a series of concentrations of pyrimethamine with or without doxycycline (5 mg/L). Following quantification of the data (Figure S10), we observed that removal of the multidrug export pump by the *pdr5Δ* deletion significantly increased the strains' sensitivity to pyrimethamine, such that (in

the presence of doxycycline) the sensitivity of the *Trypanosoma brucei* DHFR could be observed (Figure 3).

Discussion

Yeast cells are suitable hosts for the expression of heterologous proteins from various species, including enzymes essential to the different life-cycle stages of parasites. Some of these parasite life stages cannot be propagated under laboratory conditions, and thus yeast provides a practical and flexible platform for *in vivo* drug screens. Here, we have reported the construction of a series of yeast strains that are identical apart from the cds for different heterologous drug targets (*DHFR*, *PGK* or *NMT*) which they express. For all of these targets, we also constructed yeast strains expressing the cds for the equivalent human enzyme, thus permitting the design of screens for agents that discriminate between the parasite and human targets.

Sibley and co-workers [22,40,41] have done extensive work on the complementation of yeast *dhf1* mutations by overexpression of human and *Plasmodium* DHFRs and demonstrated the suitability of yeast strains for drug screens in plate assays. Now, we have demonstrated that the *DHFR* cds from *Schistosoma mansoni*, *Leishmania major*, *Trypanosoma cruzi* and *T. brucei* can also successfully complement a *dhf1* null mutant of yeast. Furthermore, we have found that yeast cells expressing *T. brucei* DHFR are partially sensitive to pyrimethamine (Figure 2) and that strains expressing *T. cruzi* or *S. mansoni* DHFRs are sensitive to the chemotherapeutic agent methotrexate (data not shown). In addition, we have also successfully complemented yeast deletion mutants with cds for two new potential drug targets from parasites: N-myristoyl transferase (NMT) and phosphoglycerate kinase (PGK). To the best of our knowledge, this is the first evidence for the functional expression of these parasite enzymes in yeast. While all of the data presented in this paper relate to




Figure 2. Pyrimethamine sensitivity of yeast strains expressing heterologous dihydrofolate reductases (DHFRs). Serial dilutions (5x) of yeast cultures expressing cds for human (Hs), *Plasmodium falciparum* (Pf), drug resistant *P. falciparum* (Pfr), *P. vivax* (Pv), *Schistosoma mansoni* (Sm), *Trypanosoma brucei* (Tb), *T. cruzi* (Tc) or *Saccharomyces cerevisiae* (Sc) DHFRs spotted onto agar plates containing pyrimethamine at the stated doses with or without doxycycline (5 mg/L). doi:10.1371/journal.pntd.0001320.g002




Figure 3. Effect of the drug efflux pump Pdr5p on sensitivity to pyrimethamine. Graphs showing the quantification of growth on agar plates (containing the indicated concentrations of pyrimethamine +/- 5 mg/L of doxycycline) of yeast strains expressing cds for heterologous DHFRs. Solid lines: *PDR5* strains; dashed lines: *pdr5Δ* mutants. doi:10.1371/journal.pntd.0001320.g003

screens against yeast cells spotted onto agar plates, we have confirmed all the results for DHFR using yeast strains grown in liquid cultures in 384-well microtiter trays. Indeed, we intend to use such liquid cultures in HTP screens based on the series of yeast strains reported here.

Yeast cells may be refractory to chemotherapeutic drugs due to their thick cell walls and the high levels of expression of multiple drug efflux pumps. Thus the genetic manipulation of yeast strains for use in screens in order to increase their drug sensitivity is highly desirable. We have improved the drug sensitivity of our yeast constructs in two ways. First, all cds encoding heterologous enzymes that represent drug targets were placed under control of the TetO2 promoter, so that their expression could be down-regulated by addition of the tetracycline analogue, doxycycline. We demonstrated that additions of doxycycline to the growth medium enhanced the pyrimethamine sensitivity of parasite DHFR enzymes expressed in yeast (Figure 2). Second, we demonstrated (again using DHFR and pyrimethamine) that the deletion of the gene *PDR5*, which encodes the major yeast ABC transporter, can increase the sensitivity of drug screens (Figure 3). Moreover the use of *pdr5Δ* mutants in conjunction with pyrimethamine has a synergistic effect on drug sensitivity (Figure 3). The ease of genetically manipulation in yeast should allow further improvements in drug sensitivity in the future; for instance, by modifying the sequence

or expression of genes (such *CWP1*, *CWP2*, or *PSA1*) that encoding cell wall proteins [59].

We believe that many more enzyme targets and parasite species can be studied using a similar approach and are currently employing some of our strains in high-throughput drug screens using a Robot Scientist [60,61,62] in search of novel antiparasitic agents.

Supporting Information

Figure S1 Map of pCM188. Plasmid backbone used for cloning of the cds for heterologous DHFRs, NMTs and PGKs under the control of the tetracycline-regulatable promoter: TetO2. (TIF)

Figure S2 Maps of the *Plasmodium falciparum* complementation plasmids. Plasmids for expression of cds for heterologous wild-type *Plasmodium falciparum* DHFR (PfDHFR) and the drug-resistant *Plasmodium falciparum* DHFR (PfRdhfr) under the control of the TetO2 promoter. (TIF)

Figure S3 Maps of the *Plasmodium vivax* complementation plasmids. Plasmids for expression of cds for heterologous *Plasmodium vivax* DHFR, NMT and PGK under the control of the TetO2 promoter. (TIF)

Figure S4 Maps of the *Schistosoma mansoni* complementation plasmids. Plasmids for expression of cds for heterologous *Schistosoma mansoni* DHFR, NMT and PGK under the control of the TetO2 promoter. (TIF)

Figure S5 Maps of the *Trypanosoma brucei* complementation plasmids. Plasmids for expression of cds for heterologous *Trypanosoma brucei* DHFR, NMT and PGK under the control of the TetO2 promoter. (TIF)

Figure S6 Maps of the *Trypanosoma cruzi* complementation plasmids. Plasmids for expression of cds for heterologous *Trypanosoma cruzi* DHFR, NMT and PGK under the control of the TetO2 promoter. (TIF)

Figure S7 Maps of the human complementation plasmids. Plasmids for expression of cds for heterologous *Homo sapiens* DHFR, NMT2 and PGK under the control of the TetO2 promoter. (TIF)

Figure S8 Maps of the *Leishmania major* complementation plasmids. Plasmids for expression of cds for heterologous *Leishmania major* DHFR, NMT and PGKB under the control of the TetO2 promoter. (TIF)

Figure S9 Effect of doxycycline on the maximum growth rate of yeast strains expressing heterologous drug targets. Maximum growth rates (relative to that of the wild type) of yeast strains expressing cds for human or parasite DHFRs, NMTs or PGKs under the control of the TetO2 promoter. (TIF)

Figure S10 Quantification of the effect of *pdr5Δ* mutations on pyrimethamine sensitivity. A) Example of plate where serial dilutions of yeast cultures expressing cds for heterologous DHFRs were spotted in quadruplicate onto agar plates containing pyrimethamine and doxycycline. Wild-type *PDR5* strains were spotted on the left half of the plate and *pdr5Δ* deletion mutants on the right half of the plate. B) The intercepts of the brightest row and column of the spots were marked as 'colony centers'. C) The area enclosed by a diamond-shaped frame around the colony center was set as the 'colony window'. D) Number of pixels brighter than the threshold within the colony window was set as the 'colony size', which corresponds to spot's total area. (TIF)

Table S1 Plasmids used in this study. Details and source of the complementation plasmids used in this work. (DOC)

Table S2 Strains used in this study. Details and source of strains used in this work. (DOC)

Text S1 pCM188. Sequence and features of the plasmid backbone used for cloning of the heterologous DHFRs, NMTs and PGKs under the control of the tetracycline-regulatable promoter: TetO2. (GBK)

Text S2 pCMPDHFR. Sequence and features of the *Plasmodium falciparum* DHFR complementation plasmid. (GBK)

Text S3 pCMPRdhfr. Sequence and features of the drug-resistant *Plasmodium falciparum* DHFR complementation plasmid. (GBK)

Text S4 pCMPvDHFR. Sequence and features of the *Plasmodium vivax* DHFR complementation plasmid. (GBK)

Text S5 pCMSmDHFR. Sequence and features of the *Schistosoma mansoni* DHFR complementation plasmid. (GBK)

Text S6 pCMTbDHFR. Sequence and features of the *Trypanosoma brucei* DHFR complementation plasmid. (GBK)

Text S7 pCMTcDHFR. Sequence and features of the *Trypanosoma cruzi* DHFR complementation plasmid. (GBK)

Text S8 pCMHsDHFR. Sequence and features of the human DHFR complementation plasmid. (GBK)

Text S9 pCMLmDHFR. Sequence and features of the *Leishmania major* DHFR complementation plasmid. (GBK)

Text S10 pCMPvNMT. Sequence and features of the *Plasmodium vivax* NMT complementation plasmid. (GBK)

Text S11 pCMSmNMT. Sequence and features of the *Schistosoma mansoni* NMT complementation plasmid. (GBK)

Text S12 pCMTbNMT. Sequence and features of the *Trypanosoma brucei* NMT complementation plasmid. (GBK)

Text S13 pCMTcNMT. Sequence and features of the *Trypanosoma cruzi* NMT complementation plasmid. (GBK)

Text S14 pCMHsNMT. Sequence and features of the human NMT2 complementation plasmid. (GBK)

Text S15 pCMLmNMT. Sequence and features of the *Leishmania major* NMT complementation plasmid. (GBK)

Text S16 pCMPvPGK. Sequence and features of the *Plasmodium vivax* PGK complementation plasmid. (GBK)

Text S17 pCMSmPGK. Sequence and features of the *Schistosoma mansoni* PGK complementation plasmid. (GBK)

Text S18 pCMTbPGK. Sequence and features of the *Trypanosoma brucei* PGK complementation plasmid. (GBK)

Text S19 pCMTcPGK. Sequence and features of the *Trypanosoma cruzi* PGK complementation plasmid. (GBK)

Text S20 pCMHsPGK. Sequence and features of the human PGK complementation plasmid. (GBK)

Text S21 pCMLmPGKB. Sequence and features of the *Leishmania major* PGKB complementation plasmid. (GBK)

Acknowledgments

We thank Karl F. Hoffmann (Aberystwyth) for *Schistosoma mansoni* DHFR, NMT and PGK clones and suggestions to the manuscript; Mark Carrington (Cambridge) for *Trypanosoma brucei* genomic DNA; Mark Fields (Cambridge) for *Leishmania major* genomic DNA; Nianshu Zhang (Cam-

bridge) for the human cDNA library and Björn Anderson (Karolinska Institute, Sweden) for *Trypanosoma cruzi* genomic DNA.

Author Contributions

Conceived and designed the experiments: SGO RDK EB. Performed the experiments: EB AJ PP. Analyzed the data: EB AJ PP SGO. Contributed reagents/materials/analysis tools: AG. Wrote the paper: EB SGO RDK. Involved in target selection: AG.

References

- Sibley CH, Ringwald P (2006) A database of antimalarial drug resistance. *Malar J* 5: 48.
- Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. *Lancet Infect Dis* 6: 411–425.
- van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, et al. (2003) Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. *Acta Trop* 86: 125–139.
- Sayed AA, Simeonov A, Thomas CJ, Ingles J, Austin CP, et al. (2008) Identification of oxadiazoles as new drug leads for the control of schistosomiasis. *Nat Med* 14: 407–412.
- Frearson JA, Brand S, McElroy SP, Cleghorn LA, Smid O, et al. (2010) N-methyltransferase inhibitors as new leads to treat sleeping sickness. *Nature* 464: 728–732.
- Mina JG, Pan SY, Wansathipathi NK, Bruce CR, Shams-Eldin H, et al. (2009) The *Trypanosoma brucei* sphingolipid synthase, an essential enzyme and drug target. *Mol Biochem Parasitol* 168: 16–23.
- El-Sayed NM, Myler PJ, Bartholomew DC, Nilsson D, Aggarwal G, et al. (2005) The genome sequence of *Trypanosoma cruzi*, etiologic agent of Chagas disease. *Science* 309: 409–415.
- Naula C, Parsons M, Mottram JC (2005) Protein kinases as drug targets in trypanosomes and Leishmania. *Biochim Biophys Acta* 1754: 151–159.
- Laxman S, Beavo JA (2007) Cyclic nucleotide signaling mechanisms in trypanosomes: possible targets for therapeutic agents. *Mol Interv* 7: 203–215.
- Maguire JH (2006) Chagas' disease—can we stop the deaths? *N Engl J Med* 355: 760–761.
- Zhang N, Bilsland E (2011) Contributions of *Saccharomyces cerevisiae* to Understanding Mammalian Gene Function and Therapy. In: Castrillo JL, Oliver SG, eds. *Yeast Systems Biology*. NY: Humana Press. pp 501–523.
- Ericson E, Gebbia M, Heisler LE, Wildenhain J, Tyers M, et al. (2008) Off-target effects of psychoactive drugs revealed by genome-wide assays in yeast. *PLoS Genet* 4: e1000151.
- Giacver G, Chu AM, Ni L, Connelly C, Riles L, et al. (2002) Functional profiling of the *Saccharomyces cerevisiae* genome. *Nature* 418: 387–391.
- Hillenmeyer ME, Fung E, Irwin JJ, Laggner J, Pierce SE, Hoon S, et al. (2008) The chemical genomic portrait of yeast: uncovering a phenotype for all genes. *Science* 320: 362–365.
- Ho CH, Magtanong L, Barker SL, Gresham D, Nishimura S, et al. (2009) A molecular barcoded yeast ORF library enables mode-of-action analysis of bioactive compounds. *Nat Biotechnol* 27: 369–377.
- Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. (2009) Predicting new molecular targets for known drugs. *Nature* 462: 175–181.
- Parsons AB, Lopez A, Givoni IE, Williams DE, Gray CA, et al. (2006) Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. *Cell* 126: 611–625.
- Khoze C, Pleass RJ, Avery SV (2009) The antimalarial drug quinine disrupts Tat2p-mediated tryptophan transport and causes tryptophan starvation. *J Biol Chem* 284: 17968–17974.
- McCue PP, Phang JM (2008) Identification of human intracellular targets of the medicinal herb St. John's Wort by chemical-genetic profiling in yeast. *J Agric Food Chem* 56: 11011–11017.
- Li W, Mo W, Shen D, Sun L, Wang J, et al. (2005) Yeast model uncovers dual roles of mitochondria in action of artemisinin. *PLoS Genet* 1: e36.
- Aruna K, Chakraborty T, Rao PN, Santos C, Ballesta JP, et al. (2005) Functional complementation of yeast ribosomal P0 protein with *Plasmodium falciparum* P0. *Gene* 357: 9–17.
- Sibley CH, Brophy VH, Cheesman S, Hamilton KL, Hankins EG, et al. (1997) Yeast as a model system to study drugs effective against apicomplexan proteins. *Methods* 13: 190–207.
- Aguar PH, Santos DN, Lobo FP, Santos TM, Macedo AM, et al. (2006) Functional complementation of a yeast knockout strain by *Schistosoma mansoni* Rho1 GTPase in the presence of caffeine, an agent that affects mutants defective in the protein kinase C signal transduction pathway. *Mem Inst Oswaldo Cruz* 101(Suppl 1): 323–326.
- Santos DN, Aguiar PH, Lobo FP, Mourao MM, Tambor JH, et al. (2007) *Schistosoma mansoni*: Heterologous complementation of a yeast null mutant by SmRbx, a protein similar to a RING box protein involved in ubiquitination. *Exp Parasitol* 116: 440–449.
- Santos TM, Machado CR, Franco GR, Pena SD (2002) Characterization and comparative functional analysis in yeast of a *Schistosoma mansoni* Rho1 GTPase gene. *Mol Biochem Parasitol* 125: 103–112.
- Gurvitz A (2009) Identification of the *Leishmania* major proteins LmjF07.0430, LmjF07.0440, and LmjF27.2440 as components of fatty acid synthase II. *J Biomed Biotechnol* 2009: 950864.
- Balliano G, Dehmloew H, Oliaro-Bosso S, Scaldaferrri M, Taramino S, et al. (2009) Oxidosqualene cyclase from *Saccharomyces cerevisiae*, *Trypanosoma cruzi*, *Pneumocystis carinii* and *Arabidopsis thaliana* expressed in yeast: a model for the development of novel antiparasitic agents. *Bioorg Med Chem Lett* 19: 718–723.
- Carrillo C, Canepa GE, Giacometti A, Bouvier LA, Miranda MR, et al. (2010) *Trypanosoma cruzi* amino acid transporter TcAAP411 mediates arginine uptake in yeasts. *FEMS Microbiol Lett*.
- Drake R, Serrano A, Perez-Castineira JR N-terminal chimaeras with signal sequences enhance the functional expression and alter the subcellular localization of heterologous membrane-bound inorganic pyrophosphatases in yeast. *Biochem J* 426: 147–157.
- Erben ED, Daum S, Tellez-Inon MT (2007) The *Trypanosoma cruzi* PIN1 gene encodes a parvulin peptidyl-prolyl cis/trans isomerase able to replace the essential ESS1 in *Saccharomyces cerevisiae*. *Mol Biochem Parasitol* 153: 186–193.
- Mokry DZ, Manandhar SP, Chicola KA, Santangelo GM, Schmidt WK (2009) Heterologous expression studies of *Saccharomyces cerevisiae* reveal two distinct trypanosomatid CaaX protease activities and identify their potential targets. *Eukaryot Cell* 8: 1891–1900.
- Geary TG, Conder GA, Bishop B (2004) The changing landscape of antiparasitic drug discovery for veterinary medicine. *Trends Parasitol* 20: 449–455.
- Klein RD, Geary TG (1997) Recombinant Microorganisms as Tools for High Throughput Screening for Nonantibiotic Compounds. *Journal of Biomolecular Screening* 2: 41–49.
- Marjanovic J, Chalupska D, Patenode C, Coster A, Arnold E, et al. Recombinant yeast screen for new inhibitors of human acetyl-CoA carboxylase 2 identifies potential drugs to treat obesity. 107: 9093–9098. *Proc Natl Acad Sci U S A* 107: 9093–9098.
- Barberis A, Gunde T, Berset C, Audetat S, Luthi U (2005) Yeast as a screening tool. *Drug Discovery Today* 2: 187–192.
- Klein RD, Winterrowd CA, Hatzebuhler NT, Shea MH, Favreau MA, et al. (1992) Cloning of a cDNA encoding phosphoenolpyruvate carboxykinase from *Haemonchus contortus*. *Mol Biochem Parasitol* 50: 285–294.
- Klein RD, Olson ER, Favreau MA, Winterrowd CA, Hatzebuhler NT, et al. (1991) Cloning of a cDNA encoding phosphofructokinase from *Haemonchus contortus*. *Mol Biochem Parasitol* 48: 17–26.
- Klein RD, Favreau MA, Alexander-Bowman SJ, Nulf SC, Vanover L, et al. (1997) *Haemonchus contortus*: cloning and functional expression of a cDNA encoding ornithine decarboxylase and development of a screen for inhibitors. *Exp Parasitol* 87: 171–184.
- Bertino JR (2009) Cancer research: from folate antagonism to molecular targets. *Best Pract Res Clin Haematol* 22: 577–582.
- Certain LK, Sibley CH (2007) *Plasmodium falciparum*: a novel method for analyzing haplotypes in mixed infections. *Exp Parasitol* 115: 233–241.
- Rungsithirunrat K, Na-Bangchang K, Hawkins VN, Munghin M, Sibley CH (2007) Sensitivity to antifolates and genetic analysis of *Plasmodium vivax* isolates from Thailand. *Am J Trop Med Hyg* 76: 1057–1065.
- Murabito E, Smallbone K, Swinton J, Westerhoff HV, Steuer R (2010) A probabilistic approach to identify putative drug targets in biochemical networks. *J R Soc Interface* 8: 880–895.
- Michels PA, Bringaud F, Herman M, Hannaert V (2006) Metabolic functions of glycosomes in trypanosomatids. *Biochim Biophys Acta* 1763: 1463–1477.
- Crowther GJ, Napuli AJ, Gilligan JH, Gagaring K, Borboa R, et al. (2011) Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. *Mol Biochem Parasitol* 175: 21–29.
- Lexchin J (2010) One step forward, one step sideways? Expanding research capacity for neglected diseases. *BMC Int Health Hum Rights* 10: 20.
- Zucca M, Savoia D (2011) Current developments in the therapy of protozoan infections. *Open Med Chem J* 5: 4–10.

47. Pink R, Hudson A, Mouries MA, Bendig M (2005) Opportunities and challenges in antiparasitic drug discovery. *Nat Rev Drug Discov* 4: 727–740.
48. Don R, Chatelain E (2009) Drug Discovery for Neglected Diseases: View of a Public-Private Partnership. In: Selzer PM, ed. *Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates*. WILEY-VCH Verlag GmbH & Co. KGaA. pp 33–43.
49. Lefevre G, Marrast AC, Grueninger H (2011) Novartis Malaria Initiative: best practice example of pharmaceutical industry's engagement in the fight against malaria. *Ann N Y Acad Sci* 1222: 19–29.
50. Ekins S, Williams AJ (2010) When pharmaceutical companies publish large datasets: an abundance of riches or fool's gold? *Drug Discov Today* 15: 812–815.
51. Peak E, Chalmers IW, Hoffmann KF (2010) Development and validation of a quantitative, high-throughput, fluorescent-based bioassay to detect schistosoma viability. *PLoS Negl Trop Dis* 4: e759.
52. Smout MJ, Kotze AC, McCarthy JS, Loukas A (2010) A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility. *PLoS Negl Trop Dis* 4: e885.
53. Pillai AD, Pain M, Solomon T, Bokhari AA, Desai SA (2010) A cell-based high-throughput screen validates the plasmodial surface anion channel as an antimalarial target. *Mol Pharmacol* 77: 724–733.
54. Gupta S (2011) Visceral leishmaniasis: experimental models for drug discovery. *Indian J Med Res* 133: 27–39.
55. Gari E, Piedrafita L, Aldea M, Herrero E (1997) A set of vectors with a tetracycline-regulatable promoter system for modulated gene expression in *Saccharomyces cerevisiae*. *Yeast* 13: 837–848.
56. Wach A, Brachat A, Alberti-Segui C, Rebischung C, Philippsen P (1997) Heterologous HIS3 marker and GFP reporter modules for PCR-targeting in *Saccharomyces cerevisiae*. *Yeast* 13: 1065–1075.
57. Brachmann CB, Davies A, Cost GJ, Caputo E, Li J, et al. (1998) Designer deletion strains derived from *Saccharomyces cerevisiae* S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. *Yeast* 14: 115–132.
58. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, et al. (2001) Pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: what next? *Trends Parasitol* 17: 582–588.
59. Zhang M, Hanna M, Li J, Butcher S, Dai H, et al. (2010) Creation of a hyperpermeable yeast strain to genotoxic agents through combined inactivation of PDR and CWP genes. *Toxicol Sci* 113: 401–411.
60. King RD, Rowland J, Oliver SG, Young M, Aubrey W, et al. (2009) The automation of science. *Science* 324: 85–89.
61. King RD, Whelan KE, Jones FM, Reiser PG, Bryant CH, et al. (2004) Functional genomic hypothesis generation and experimentation by a robot scientist. *Nature* 427: 247–252.
62. Sparkes A, Aubrey W, Byrne E, Clare A, Khan MN, et al. (2010) Towards Robot Scientists for autonomous scientific discovery. *Autom Exp* 2: 1.